Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
相关临床试验
12
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1990
已完成
5
41.7%
尚未招募
1
8.3%
招募中
1
8.3%
终止
5
41.7%
暂无批准数据
- Stereotaxis published first peer-reviewed clinical results for its MAGiC robotic magnetic navigation catheter in the Journal of Interventional Cardiac Electrophysiology. - The prospective multi-center study achieved 94% acute efficacy across 67 patients with various arrhythmias, with only 1.5% procedure-related adverse events. - The MAGiC catheter demonstrated improved stability and performance compared to previous magnetic catheters, with average procedure times of 83 minutes skin-to-skin. - Results support the ongoing European launch of the MAGiC catheter system for minimally invasive cardiac ablation procedures.
- Stereotaxis received regulatory approval in China for its Magbot magnetic navigation ablation catheter, designed for minimally invasive cardiac procedures. - The approval follows recent clearance for Stereotaxis' Genesis robotic magnetic navigation system, expanding its footprint in the Chinese market. - Magbot, developed with MicroPort EP, integrates with robotic systems for precise navigation and real-time 3D cardiac modeling. - NMPA approved Magbot for treating drug-resistant persistent AFib, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia.
